An invalid vocabulary is selected. Please change it in the options.
Title Credits Start date - Expiration date
Recorded Presentation from the NCCN Pharmacy Updates: Novel Therapies for Treating ESR1 and RET-Fusion Mutations in Breast Cancer 1.00 11/01/2024 - 12:00am to 11/01/2025 - 12:00am
NCCN Guidelines® Insights - Management of Immunotherapy-Related Toxicities, Version 2.2024 1.00 11/10/2024 - 12:00am to 11/10/2025 - 12:00am
Recorded Presentation from the NCCN Pharmacy Updates: Chemoimmunotherapy Updates in Advanced/Metastatic Non-Small Cell Lung Cancer 1.00 11/12/2024 - 12:00am to 11/12/2025 - 12:00am
Archived NCCN Tumor Boards: Multidisciplinary Management of Head and Neck Cancers 1.00 11/26/2024 - 12:00am to 11/26/2025 - 12:00am
Archived NCCN Tumor Boards: New Approaches to Treatment of Bladder Cancer 1.00 11/26/2024 - 12:00am to 11/26/2025 - 12:00am
Recorded Presentation from the NCCN Pharmacy Updates: Maintenance Strategies in the Management of Acute Myeloid Leukemia 1.00 11/26/2024 - 12:00am to 11/26/2025 - 12:00am
Managing Earlier Integration of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia 0.75 12/01/2024 - 12:00am to 12/01/2025 - 12:00am
What is Optimal First-Line Management of Advanced Classic Hodgkin Lymphoma? 0.75 12/01/2024 - 12:00am to 12/01/2025 - 12:00am
Review of Oral Targeted Therapies in Acute Myeloid Leukemia 0.75 12/01/2024 - 12:00am to 12/01/2025 - 12:00am
Myelodysplastic Syndromes: Treatment Updates and Emerging Data 0.50 12/01/2024 - 12:00am to 12/01/2025 - 12:00am
Management of Multiple Myeloma: Smoldering, Newly Diagnosed, and Relapsed/Refractory Disease 2.25 12/01/2024 - 12:00am to 12/01/2025 - 12:00am
Diffuse Large B-Cell Lymphoma: Sequencing Therapy for Relapsed/Refractory Disease 0.50 12/01/2024 - 12:00am to 12/01/2025 - 12:00am
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updates in Prognosis and Treatment 1.00 12/01/2024 - 12:00am to 12/01/2025 - 12:00am
Managing Post-Treatment Complications for Multiple Myeloma and Acute Lymphocytic Leukemia 1.00 12/01/2024 - 12:00am to 12/01/2025 - 12:00am
Debate: Is the Addition of Polatuzumab Vedotin the New Standard First-Line Therapy for Diffuse Large B-Cell Lymphoma? 0.75 12/01/2024 - 12:00am to 12/01/2025 - 12:00am

Pages